Dr. Carl Schwartz
Therapeutics. really four or so much lot under afternoon a welcome. for time Scott. Precision now about. you got exciting think Thank Good We divisions and have we’ve our shareholders a our very is, talk under to control, This I to to soon
a is active been both Skyline XXXX. Medical foreign and and First in has domestic own very that has its of division now
was year. it such As a pivotal
continents although we Pakistan, five expand continue Sales. sales had personnel, we XXXX. the of and seven Here now Skyline. of of still few, hired in name Head European countries, are the new several distributors expanded out efforts a disposables records sales machines a did experienced unabated new that our continue our a hired and but more to into world's not East, our to in that we of point hit a Sales, and signed want many projections We force some we with only We sales for independent machines efforts office, Middle I and Canada, XXXX, India, Director nationally have to highlights; European our Taiwan in established set in just Australia, not worldwide. Domestic
are to replace tumors to get more of biomarkers which take results to rats use, XXXX are less to test the expensive addition, and to formed we these mice develop In reliable. TumorGenesis lab longer use ovarian in and results, division and the
purchased XX% company Helomics, bioinformatics of also in ovarian cancer. We specializing a
have We more moving which smaller, with new our will smartly parts. X fewer machine, of along on be development compact Generation the been moving
In hospitals with addition, vacuum. start. machine this attachable gotten limited to has XXXX backing for also great off help new to will a separate pump purchase available have a
Helomics We will XXX% days and in next this finalize own corporation. the our of of will purchase we of couple exciting
marketing We training have our improved more continued hospital the widening of force maintain by of to our sales world, machines. expand to Skyline to cover our our personnel and
available machine be X out will and shortly Generation testing be new May for in Our will thereafter.
the a growing XX about which the any the tumors grow university thinking for the lab cancer essentially for XX these Head Gabriel, and of has TumorGenesis. on and still feet. they're cell of types move with signing U.S. evaluations to the the a behalf ovarian kits not of on formed in These has rats growing under Richard biomarker grass have replace inside of built first laboratory rapidly new, develop TumorGenesis Now, talk continued ovarian fools mice. patient and cells let developers suppliers suppliers approach testing to let's rapid and of biomarkers sent was contracts use to them large into TumorGenesis cancer TumorGenesis. biomarkers. and his TumorGenesis using screening
these themselves to samples. to TumorGenesis other biomarker the addition, screening worldwide, proprietary media that kits they own discovery will cancer In commercially screen researchers want and may offered the kits cell grow be ovarian purchase so their will
work the will It's do screening I tumor. capture this the for bring match This own search groundbreaking outside preparation. reality biomarkers the which to result This these will patient's closer the a research of cancer so new myself. step if TumorGenesis them production on really in supports kit. university, mount take up TumorGenesis and done us to protocol say will will in of one then the cell Following in on the tumors building body found at first
Corporation. we Precision Now latest Helomics to acquisition, come Therapeutics
drugs with the purpose leading learning days. intend intelligence make stated I mission corporate single-minded Collins, we discover and as to of to earlier better own by of couple company become can cancer. in Helomics and artificial of VP dedicated a Mark will we women's our As Innovation, stated people XXX% Its machine that
breast, of these to our largest databases cancers, these past to the learning million of bring was XX cancers deep the software applying cancers. one we thousands in Over to the women of over realistic ovarian, and with By years, in will invested brain country. $XXX hope build Helomics
the in next three database several sharing these months, expand will Over data our collaborations we and field to enter have into companies already to on with cancers. with other continue agreements the
what tumors sequencing consisting business our really overseeing Our pharmaceutical Mark perform progress Clinician, Merck approach for cancer can Paul by world pharmacogenomics a we increase companies will our wife will prior following Malandro, Pharmacogenomics achieve Murphy, University. VP our of and Zuckerberg determine drug Priscilla Zuckerberg at a Laboratories of most have watch Research established Science be them. at of and and world on. Professor Biomedical our like class develop Amelia assembled Head each Neurosurgeon, and to effective Clinical help goals, Cancer Sciences, number help Researcher. Chan. deep luminaries; that all genomics subtype To learning Engineering, Facebook to combinations Marc and served available as Bob owned leaders for sold strategic software validate built of and for Kornblith, Operations And Machine Advisory Dr. recently to Biological with two the of Learning Chan she Clinical world companies, to Dr. collaboration Warner his class founder these and entrepreneurial -- to Board Carnegie Investors Helomics projects. Initiative the finally to renowned Mellon
with Medicine our a had similar did is Roche in Foundation to how partner to XX,XXX One that tumors. time Foundation on secure goals XXXX. At of information
then our in Bob as for stuff. Myers, call tumors our questions. is exciting XX, discuss will results now our bank Foundation will we Again open XXXX. XXX,XXX Bob. mind call to data pass over the And job our CFO really, who to have December year-ended for the financial We I and fiscal that did. really the with will them And
